Literature DB >> 25364476

Identification of death receptors DR4 and DR5 in HTB-12 astrocytoma cell lines and determination of TRAIL sensitivity.

Elenia Riddick1, Shavonda Evans1, Jeffrey Rousch1, Ephraim Gwebu1, Hirendra Nath Banerjee1.   

Abstract

Astrocytomas are tumors which arise from astrocytes, cells that form the blood-brain barrier. There are very few drugs that successfully treat brain tumors. In this study, the cytotoxic effects on the HTB-12 astrocytoma cell line by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) were studied. The presence of the TRAIL receptors, Death receptor 4 (DR4) and Death receptor 5 (DR5), were detected in HTB-12 cells by Enzyme-Linked Immunosorbent Assay (ELISA). Cytotoxicity assay by Trypan Blue Exclusion Method showed effective cell killing by TRAIL treatment. Thus, the presence of death receptors and TRAIL efficacy raises the therapeutic potential for this type of brain tumor.

Entities:  

Keywords:  Astrocytes; Astrocytoma; Death receptors; TRAIL

Year:  2013        PMID: 25364476      PMCID: PMC4214680          DOI: 10.5430/jst.v3n6p20

Source DB:  PubMed          Journal:  J Solid Tumors        ISSN: 1925-4067


  25 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.

Authors:  I F Pollack; M Erff; A Ashkenazi
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

3.  TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

Authors:  H Walczak; M A Degli-Esposti; R S Johnson; P J Smolak; J Y Waugh; N Boiani; M S Timour; M J Gerhart; K A Schooley; C A Smith; R G Goodwin; C T Rauch
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

4.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

Authors:  J P Sheridan; S A Marsters; R M Pitti; A Gurney; M Skubatch; D Baldwin; L Ramakrishnan; C L Gray; K Baker; W I Wood; A D Goddard; P Godowski; A Ashkenazi
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

5.  Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade.

Authors:  P Li; D Nijhawan; I Budihardjo; S M Srinivasula; M Ahmad; E S Alnemri; X Wang
Journal:  Cell       Date:  1997-11-14       Impact factor: 41.582

6.  Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.

Authors:  R M Pitti; S A Marsters; S Ruppert; C J Donahue; A Moore; A Ashkenazi
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

7.  Cutting edge: TRAIL deficiency accelerates hematological malignancies.

Authors:  Nadeen Zerafa; Jennifer A Westwood; Erika Cretney; Sally Mitchell; Paul Waring; Manuela Iezzi; Mark J Smyth
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

8.  Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells.

Authors:  T S Griffith; W A Chin; G C Jackson; D H Lynch; M Z Kubin
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

9.  Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

Authors:  Jin H Song; Anita Bellail; Margaret C L Tse; V Wee Yong; Chunhai Hao
Journal:  J Neurosci       Date:  2006-03-22       Impact factor: 6.167

10.  Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family.

Authors:  M A Degli-Esposti; P J Smolak; H Walczak; J Waugh; C P Huang; R F DuBose; R G Goodwin; C A Smith
Journal:  J Exp Med       Date:  1997-10-06       Impact factor: 14.307

View more
  1 in total

1.  Chaperonin-containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients.

Authors:  Yueyun Hu; Peng Fu; Hongyang Zhao; Fangcheng Zhang; Xiaobing Jiang; Wohua Zhao; Peng Lv
Journal:  J Clin Lab Anal       Date:  2021-07-27       Impact factor: 3.124

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.